China’s Biopharma Sector To Grow At 20 Percent - Study
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The Chinese biopharmaceutical sector continues to grow by 20 percent each year, according to a study published in August by BioPlan Associates and the Society for Industrial Microbiology
You may also be interested in...
GNI And EpiCept Ink Development Deal For Anti-Viral Hepatitis B Drug
SHANGHAI - GNI and EpiCept have entered into an agreement that will see the latter develop a new anti-viral hepatitis B drug, EP1013, in Asia, Australia and New Zealand
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).